Given that more than 70% of canine prostate cancers harbor the BRAFV595E mutation, the companion dog model could be a highly relevant platform for comparative cancer research to understand molecular events leading to BRAF mutation and further develop a BRAF-targeted therapy. This evidence concerns the gene BRAF and prostate cancer.